Award for breast cancer test pioneer
01.07.2015 - Laura van't Veer, co-founder and Chief Research Officer of Agendia, has won the European Inventor Award in the SME category. The Dutch molecular biologist and geneticist is the co-inventor of Agendia’s FDA-approved breast cancer test.
Agendia B.V. is a Dutch and US-American molecular diagnostics company that was co-founded by van’t Veer, who received her PhD on the study of Oncogene Activation and Tumorigenesis at the University of Leiden, in Amsterdam in 2003. She initially served as its Chief Operating Officer until mid 2007, after which she became the company’s Chief Research Officer. Agendia has developed a genetic diagnostic test, MammaPrint, used for breast cancer patients, which estimates the risk of recurrence up to 20 years into the future. van’t Veer’s award recognises the fundamental way in which she has changed breast cancer care with her invention of MammaPrint.
The prestigious innovation award, presented by the European Patent Office (EPO) took place on 11 June in Paris. Now in its 10th year, the accolade honours outstanding inventors who have made an exceptional contribution to social development, technological progress and economic growth.http://www.european-biotechnology-news.com/people/bio-people/2015/laura-vant-veer.html